Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
3.350
-0.020 (-0.59%)
At close: Jun 5, 2026, 4:00 PM EDT
3.290
-0.060 (-1.79%)
After-hours: Jun 5, 2026, 5:54 PM EDT
Lisata Therapeutics Employees
Lisata Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 5 or -19.23% compared to the previous year.
Employees
21
Change (1Y)
-5
Growth (1Y)
-19.23%
Revenue / Employee
$8,095
Profits / Employee
-$778,619
Market Cap
30.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -5 | -19.23% |
| Dec 31, 2024 | 26 | 1 | 4.00% |
| Dec 31, 2023 | 25 | -2 | -7.41% |
| Dec 31, 2022 | 27 | 0 | - |
| Dec 31, 2021 | 27 | 3 | 12.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| Quantum BioPharma | 17 |
| BriaCell Therapeutics | 16 |
LSTA News
- 21 days ago - Lisata Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 25 days ago - Lisata Therapeutics Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 3 months ago - Lisata Therapeutics Annual report: Q4 2025 - Filings
- 3 months ago - Lisata Therapeutics to be acquired by Kuva Labs for $5 per share cash plus CVR - TheFly
- 3 months ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 4 months ago - Lisata Therapeutics announces mutual termination of license agreement with Qilu - TheFly
- 4 months ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire